On 21 November, Johnson & Johnson, a multinational pharmaceutical, biotechnology and medical technologies corporation, announced it is discontinuing its Auτonomy proof-of-concept study of posdinemab (JNJ-63733657), an anti-tau monoclonal antibody, in early Alzheimer’s disease (AD). The Auτonomy trial was designed as a first-of-its-kind precision medicine approach to evaluating targeted intervention in early AD. More than 500 participants were enrolled and randomly assigned to receive either posdinemab or placebo via intravenous infusion. The primary outcome was change in the Integrated Alzheimer’s Disease Rating Scale (iADRS), a composite measure of cognition and daily functioning. The company reported the failure of the trial in a brief press release, revealing posdinemab didn’t achieve statistical significance in slowing clinical decline at a scheduled review. A full evaluation of the trial data will be shared with the scientific community in due course, according to the company.
https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-the-au%CF%84onomy-study